TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01816555

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Subjects will be assigned to a dosage level between 600IU daily and 10,000IU daily depending on their age, weight and current vitamin D level

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Subjects will be assigned to a dosage level between 600IU daily and 10,000IU daily depending on their age, weight and current vitamin D level
Study: NCT02655575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BI + VR + CBT
Description: Brief intervention (information and advice) + group-based vestibular rehabilitation combined with cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BI + VR + CBT
Description: Brief intervention (information and advice) + group-based vestibular rehabilitation combined with cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BI + phone calls
Description: Brief intervention (information and advice). Patients are followed-up by phone calls
Study: NCT02613767

Intervention type: OTHER
Intervention: L-[ring 13C6]Phenylalanine infusion
Description: experimental method for determining protein synthesis rates
Study: NCT01354288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational tool
Description: Specific educational tool in order to assess its impact on glycemic control, quality of life, knowledge about the disease and its daily management
Study: NCT03558438

Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study: NCT02655575

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BI + phone calls
Description: Brief intervention (information and advice). Patients are followed-up by phone calls
Study: NCT01026740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Description: single intravenous (i.v.) infusion, 500 mg ceftobiprole administered over 2 hours.
Study: NCT01441700

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone and Supine emergence from anaesthesia
Description: Aims: The aim of this study was to compare haemodynamic changes and to evaluate the incidence of coughing, laryngospasm, loss of monitoring in patients undergoing lumbar disc surgery extubated in prone position and supine position. Settings and design: This open-level prospective randomized study was carried out in 50 patients who were admitted for elective lumbar surgery. Methods: The patients were randomly allocated to one of the two groups of 25 each at conclusion of surgery. First group was extubated in prone position and second in supine position at conclusion of surgery. Supine group patients were rolled back and prone group patients were left undisturbed. Extubation was done after complete reversal of neuromuscular block. Heart rates, Mean Arterial Pressure were noted at various points of time. Coughing, laryngospasm, vomiting, monitor disconnection if any were also noted. Statistical methods: Data was analyzed using

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone and Supine emergence from anaesthesia
Description: Aims: The aim of this study was to compare haemodynamic changes and to evaluate the incidence of coughing, laryngospasm, loss of monitoring in patients undergoing lumbar disc surgery extubated in prone position and supine position. Settings and design: This open-level prospective randomized study was carried out in 50 patients who were admitted for elective lumbar surgery. Methods: The patients were randomly allocated to one of the two groups of 25 each at conclusion of surgery. First group was extubated in prone position and second in supine position at conclusion of surgery. Supine group patients were rolled back and prone group patients were left undisturbed. Extubation was done after complete reversal of neuromuscular block. Heart rates, Mean Arterial Pressure were noted at various points of time. Coughing, laryngospasm, vomiting, monitor disconnection if any were also noted. Statistical methods: Data was analyzed using
Study: NCT04237246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 24 hour long acting advegraf
Study: NCT00868036

Intervention type: PROCEDURE
Intervention: Patch Testing
Description: Patch testing will be performed with a modified North American Contact Dermatitis Group (NACDG) standard series, cosmetics/preservative, fragrance, and textile series in all patients. Based on patient history, other appropriate allergen series will be added. After two days, patches will be removed and the areas will be inspected for type IV hypersensitivity reactions including papules, edema or vesicles.~Results will be graded and interpreted at a delayed read, 3-4 days after allergens are placed with patch testing.
Study: NCT03693989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05%
Description: Dosage: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednefrin
Description: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.~- Route of administration: topical ophthalmic
Study: NCT02782260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Study: NCT04755452

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low intra-abdominal pressure
Description: 7 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High (standard) intra-abdominal pressure
Description: 12 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
Study: NCT02782260

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00457314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Regular exercise training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Regular exercise training
Study: NCT01017159

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous immunoglobulin
Description: The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous immunoglobulin
Description: The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
Study: NCT00801606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc 20 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronutrient without zinc
Description: Multimineral 2 RDA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronutrient with zinc
Description: Multimineral 2 RDA and zinc 20 mg per day
Study: NCT03729245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bempegaldesleukin
Description: Specified dose on specified days
Study: NCT01075022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colecalciferol (Vitamin D3) 300.000 UI
Description: Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose
Study: NCT03729245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sunitinib
Description: Specified dose on specified days
Study: NCT04222569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-piece
Description: Spontaneous breath trial with a T-piece

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-piece
Description: Spontaneous breath trial with a T-piece
Study: NCT03729245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cabozantinib
Description: Specified dose on specified days
Study: NCT02180477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHAC 62 XX - TF1 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHAC 62 XX - TF1 tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UHAC 62 XX - TF1 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHAC 62 XX - TF2 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHAC 62 XX - TF2 tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UHAC 62 XX - TF2 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHAC 62 XX - capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHAC 62 XX - capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UHAC 62 XX - capsules
Study: NCT03703323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotative thromboelastometry analysis
Description: Obtaining blood sample (one tube of blood)
Study: NCT03689855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: The initial dose will be administered over 60 minutes (+/- 15 minutes). If the first infusion is tolerated without infusion-associated events, the second infusion may be delivered over 30 minutes (+/- 10 minutes).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: -Baseline and Cycle 2 Day 1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: * If archival biopsy tissue not available, participant will undergo biopsy at baseline~* When feasible, a repeated tumor biopsy will be obtained between Cycles 2 and 3 after the scheduled CT scan.
Study: NCT03148015

Intervention type: OTHER
Intervention: Biomarkers
Description: Evaluate the intracellular and intraluminal distribution of autophagy and calcium efflux markers in each breast lesion in comparison to the HER2, proliferation (Ki-67, PCNA), p53, inflammatory, and apoptotic (Annexin-1) markers in the same patient. Determine the qualitative amount and localization of PMCA2 and Vitamin D Receptor in each breast lesion with intraductal calcium spicules compared to lesions without microcalcifications.

Intervention type: OTHER
Intervention: Biomarkers
Description: Evaluate the intracellular and intraluminal distribution of autophagy and calcium efflux markers in each breast lesion in comparison to the HER2, proliferation (Ki-67, PCNA), p53, inflammatory, and apoptotic (Annexin-1) markers in the same patient. Determine the qualitative amount and localization of PMCA2 and Vitamin D Receptor in each breast lesion with intraductal calcium spicules compared to lesions without microcalcifications.

Intervention type: OTHER
Intervention: Biomarkers
Description: Evaluate the intracellular and intraluminal distribution of autophagy and calcium efflux markers in each breast lesion in comparison to the HER2, proliferation (Ki-67, PCNA), p53, inflammatory, and apoptotic (Annexin-1) markers in the same patient. Determine the qualitative amount and localization of PMCA2 and Vitamin D Receptor in each breast lesion with intraductal calcium spicules compared to lesions without microcalcifications.
Study: NCT02666612

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples
Study: NCT02193412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: noxious stimulus
Description: standardized noxious stimulus with tetanic stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: change in operating table slope: head-down tilt position
Description: -30°

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: change in operating table slope: head-up tilt position
Description: +30°
Study: NCT04217213

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal nerve block
Description: In the experimental group, the surgeons used 0.5% ropivacaine combined with mecobalamine (0.5mg) before the operation to perform intercostal nerve block in the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity, and injected 5ml in each intercostal nerve block.In the control group, surgeons used 0.5% ropivacaine alone before the operation to perform intercostal nerve block through the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity. 5ml was injected into each intercostal nerve block.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block
Description: In the experimental group, the surgeons used 0.5% ropivacaine combined with mecobalamine (0.5mg) before the operation to perform intercostal nerve block in the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity, and injected 5ml in each intercostal nerve block.In the control group, surgeons used 0.5% ropivacaine alone before the operation to perform intercostal nerve block through the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity. 5ml was injected into each intercostal nerve block.
Study: NCT03074682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifeflow
Description: Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Push/Pull
Description: Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Bag
Description: Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
Study: NCT00989781

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-D Ultrasound
Description: One time pelvic ultrasound

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-D Ultrasound
Description: One time pelvic ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human chorionic gonadotropin
Description: Recombinant human chorionic gonadotropin will be given iv and blood samples obtained before and 24 hr afterwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human chorionic gonadotropin
Description: Recombinant human chorionic gonadotropin will be given iv and blood samples obtained before and 24 hr afterwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human follicle stimulating hormone
Description: Recombinant human follicle stimulating hormone will be given iv and blood samples obtained before and 24 hr later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human follicle stimulating hormone
Description: Recombinant human follicle stimulating hormone will be given iv and blood samples obtained before and 24 hr later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropin
Description: Each subject will receive a 7 hr dose-response infusion of Adrenocorticotropin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropin
Description: Each subject will receive a 7 hr dose-response infusion of Adrenocorticotropin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given prior to ACTH infusion test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given prior to ACTH infusion test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Each subject will undergo 3 oral glcuose tolerance tests.
Study: NCT01075022

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule, Single Dose
Study: NCT00795717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza
Description: Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules given twice daily
Study: NCT03067701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Monoxide
Description: In healthy young adults 18-39 years of age, The investigator will determine if intermittent inhalation of 0.1% CO, from a 1-Liter bag once every minute for 30-40 min at a level that approaches the CO boost with hookah smoking, augments endothelial function.
Study: NCT01066819

Intervention type: DRUG
Intervention: Peginterferon alfa-2a [Pegasys]
Description: Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.

Intervention type: DRUG
Intervention: Peginterferon alfa-2b [PegIntron®]
Description: Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
Study: NCT00801606

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01984099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Patients will be given a single course of methotrexate within fourteen days from molar evacuation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B Complex
Description: Patients will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
Study: NCT01465399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factors PRGF-Endoret
Study: NCT04222569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV 7 and PEEP 0
Description: Spontaneous breath trial with a pressure support ventilation of 7 cmH2O and no positive end expiratory pressure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV 7 and PEEP 0
Description: Spontaneous breath trial with a pressure support ventilation of 7 cmH2O and no positive end expiratory pressure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV 7 and PEEP 0
Description: Spontaneous breath trial with a pressure support ventilation of 7 cmH2O and no positive end expiratory pressure
Study: NCT01465399

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional closure of the lesion
Study: NCT00185692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-myeloablative hematopoietic cell transplantation
Description: TLI and ATG infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: 1.5 mg/kg QD x 5, IV. Dosage will be based on body weight. Purified, sterile IgG fraction of immune serum of rabbits immumixied with human thymus lymphocyte. This drug acts to modify the number and function of lymphocytes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 6.25 mg/kg BID, PO.Mechanism of action is inhibition of T-cell activation by binding to a cytoplasmic protein (cyclophillin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg Q 8 hours, PO. Inhibtis the enzme inosine monophsophate dehydrogenase (MPDII) noncompetitively which blocks the de nobo synthesis of guanosine required for DNA synthesis and has an effect on T and B cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 16 mg/kg, SQ Growth factor used to make bone marrow produce more blood cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solumedrol
Description: 1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 650 mg PO, 30 minutes prior to infusion Pain reliever

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenydramine
Description: 50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms
Study: NCT04222569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV 7 and PEEP 0
Description: Spontaneous breath trial with a pressure support ventilation of 7 cmH2O and no positive end expiratory pressure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV 7 and PEEP 0
Description: Spontaneous breath trial with a pressure support ventilation of 7 cmH2O and no positive end expiratory pressure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV 7 and PEEP 0
Description: Spontaneous breath trial with a pressure support ventilation of 7 cmH2O and no positive end expiratory pressure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV 0 and PEEP 0
Description: Spontaneous breath trial without pressure support ventilation and positive end expiratory pressure, with a patient intubated and connected to the ventilator

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV 0 and PEEP 0
Description: Spontaneous breath trial without pressure support ventilation and positive end expiratory pressure, with a patient intubated and connected to the ventilator

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV 0 and PEEP 0
Description: Spontaneous breath trial without pressure support ventilation and positive end expiratory pressure, with a patient intubated and connected to the ventilator

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV 0 and PEEP 0
Description: Spontaneous breath trial without pressure support ventilation and positive end expiratory pressure, with a patient intubated and connected to the ventilator

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV 0 and PEEP 0
Description: Spontaneous breath trial without pressure support ventilation and positive end expiratory pressure, with a patient intubated and connected to the ventilator

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV 0 and PEEP 0
Description: Spontaneous breath trial without pressure support ventilation and positive end expiratory pressure, with a patient intubated and connected to the ventilator